Hemagglutinin (Influenza A virus H5N1) (H5 HA)

Hemagglutinin (HA) is a class I viral fusion protein and the primary surface antigen of the H5N1 influenza A virus. It exists as a homotrimer, where each monomer is proteolytically cleaved into HA1 and HA2 subunits; HA1 mediates binding to host cell sialic acid receptors, while HA2 facilitates the fusion of the viral envelope with the endosomal membrane (UniProt: P03452). In the context of H5N1, a highly pathogenic avian influenza (HPAI) strain, the HA protein is the critical target for vaccine development and neutralizing antibody therapies due to its role in viral entry. Vaccines employing H5N1 HA antigens aim to induce high titers of hemagglutination inhibition (HAI) antibodies that prevent viral attachment to host cells (FDA, 2020). Because H5N1 has significant pandemic potential and a high mortality rate in humans, HA is also a primary focus for universal influenza vaccine research, specifically targeting the more conserved 'stalk' region of the protein to provide broader protection against divergent H5 clades. However, the high rate of mutation in the HA gene, known as antigenic drift, poses a continuous challenge for maintaining vaccine efficacy against emerging viral variants.

Other names

H5N1 hemagglutininH5 antigenInfluenza A virus H5N1 surface glycoproteinHA proteinHemagglutinin H5

Vaccines containing H5N1 hemagglutinin antigens work by inducing the production of virus-specific neutralizing antibodies. These antibodies primarily target the globular head of the HA1 subunit, sterically hindering the virus from binding to host cell sialic acid receptors (CDC, 2024; WHO, 2023). This prevents viral entry and subsequent replication within the host respiratory epithelium.